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Abstract
Introduction—Transforming growth factor beta-1 (TGF-β1) is an important genetic modifier of
lung disease severity in cystic fibrosis (CF), yet the mechanism behind this disease association
remains unknown. Initial steps in the investigation of the relationship between TGF-β1 and CF
lung disease include determining the most appropriate available biospecimen for TGF-β1 protein
measurement.
Hypothesis—In hospitalized pediatric CF patients, plasma TGF-β1 is increased in association
with clinical parameters of lung disease severity.
Methods—Serum and plasma were obtained pre- and post intravenous antibiotic therapy in
pediatric CF patients hospitalized for a pulmonary exacerbation. Total TGF-β1, measured via
ELISA, was compared with markers of lung disease, including airway microbiology, lung function
and response to therapy.
Results—Forty CF children were studied, 15 of whom underwent bronchoalveolar lavage (BAL)
at the time of admission. Plasma TGF-β1 positively correlated with BAL fluid TGF-β1 (r = .59, p
< .05). Admission plasma TGF-β1 was increased in subjects positive for Pseudomonas aeruginosa
(p = .014) and was inversely associated with diminished lung function (p < .038) after therapy.
Treatment with antibiotics significantly decreased plasma TGF-β1 (p < .001). Serum TGF-β1 was
not associated with plasma TGF-β1, BALF TGF-β1 or these clinical parameters of lung disease.
Conclusion—In pediatric CF, plasma (but not serum) TGF-β1 is increased in association with
Pseudomonas infection and lung disease, and is reduced in response to therapy. These findings
emphasize the importance of optimizing biospecimen selection for future studies investigating the
role of TGF-β1 in CF lung disease.
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Cystic fibrosis (CF) is characterized by heterogeneous lung disease in children who share
similar cystic fibrosis transmembrane regulator (CFTR) gene mutations. This observation
has prompted significant interest in the identification of non-CFTR genetic modifiers of CF
lung disease, potentially providing novel insight into the mechanisms of CF lung disease
progression. Among candidate genetic modifiers, transforming growth factor beta 1 (TGF-
β1) has repeatedly been implicated1,2,3,4, yet the mechanisms linking this genetic modifier
with disease progression remains elusive5. An important early step in further understanding
the association between TGF-β1 and CF lung disease severity is to define a link between
protein levels and clinically-important parameters of disease in a biospecimen that can be
feasibly obtained in large numbers necessary for future multi-center studies.
TGF-β1 is a pleiotropic cytokine that affects a wide array of cellular functions with
relevance to CF, including lung development6, immunomodulation7 and airway
remodeling8. In pulmonary tissue, TGF-β1 is produced principally by bronchial epithelial
cells and alveolar macrophages9. In the blood, the principle source of TGF-β1 is from alpha
granules of activated platelets involved in coagulation10. Thus, measurements of TGF-β1 in
blood are dependent upon the coagulation status of the specimen11. As serum is generated
by triggering the coagulation cascade, serum TGF-β1 levels are largely reflective of
activated platelet contribution12. In contrast, plasma can be processed to limit ex vivo
coagulation and thus potentially provide TGF-β1 measurements more reflective of
circulating levels13. Consequently, plasma TGF-β1 may be more representative of
circulating TGF-β1 protein levels than serum, offering an improved opportunity to link a
clinically-relevant and easily available biospecimen that may reflect clinical phenotype with
both TGF-β1 genotype and clinical parameters of lung disease.
Although TGF-β1 has consistently been identified as a genetic modifier of CF lung disease,
these reports have not universally agreed upon a common genetic polymorphism1, 2,4,14 or
the relationship of genetic polymorphism to protein measurement2,4,15,16. Potential
explanations for this varied analysis includes inconsistent specimen choice, unclear links
between protein concentration and clinically important parameters of CF disease, and varied
genetic background of the reference populations.
The current study was conducted to explore whether relationships exist between protein
levels of TGF-β1 in plasma or serum and clinically-relevant parameters of pediatric CF lung
disease. Specifically, we hypothesized that plasma TGF-β1 is correlated with levels of TGF-




The study, approved by the University of North Carolina Biomedical Institutional Review
Board (IRB), was designed as a prospective, one-year, single-center observational protocol
to measure plasma and serum TGF-β1 in pediatric CF patients admitted to the hospital for
the initiation of intravenous (IV) antibiotics for treatment of a pulmonary exacerbation as
defined by their CF care provider. Parents of all pediatric patients provided signed informed
consent to participate in the study, with children assenting for the study when appropriate.
Measurement of plasma and serum TGF-β1 on admission were compared with three clinical
parameters: 1) presence or absence of Pseudomonas aeruginosa (PsA) on admission
respiratory culture; 2) FEV1 obtained on admission and at the conclusion of therapy
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compared to predicted values; and 3) recent/recurrent hospitalizations as defined as previous
hospitalization in the past 12 months. A subgroup of admitted patients underwent clinically-
indicated bronchoscopy with bronchoalveolar lavage at the time of admission (n=15). In
these patients, serum and plasma TGF-β1 were compared to bronchoalveolar lavage fluid
(BALF) TGF-β1. When available (n=24), specimens were additionally collected at the
completion of antibiotic therapy and compared to admission values to evaluate the response
to therapy.
Specimen Collection and Processing
Blood specimens were collected within 72 hours of admission and at the conclusion of IV
antibiotics. Specimens were preferentially collected through a central venous catheter such
as a peripherally inserted central catheter (PICC) or Port-a-Cath. If samples were not able to
be obtained via the central catheter at the end of therapy, the post-treatment specimen was
omitted. For plasma collection, blood was collected in 2.6 ml glass Acid Citrate Dextrose
(ACD) tubes (BD Vacutainer, Franklin Lakes, NJ) and centrifuged at 5000 g×10 minutes.
For serum collection, blood was collected in 3.5 ml plastic Serum Separator (SST) tubes
(BD Vacutainer, Franklin Lakes, NJ) and centrifuged at 1000 g×5 minutes. After
centrifugation, plasma and serum samples were stored at −80°C until further analysis.
Bronchoalveolar lavage was performed per institutional clinical practice as previously
described17,18,19. In brief, the location for lavage was at the bronchoscopist's discretion.
Generally, lavage was directed at areas of either radiographic abnormalities or visibly heavy
secretions. For each lavage, 1 ml/kg aliquots up to a maximum of 20 ml of normal saline
were instilled and suctioned back through the bronchoscope. If more than one location was
lavaged, the specimens were pooled for analysis. BAL fluid was centrifuged at 500 g×5
minutes with the cell-free supernatant stored at −80° C for subsequent assays.
TGF-β1 measurement
Total TGF-β1 in plasma, serum and BALF was measured using commercially-available
ELISA kits (R&D systems, Minneapolis, MN) as previously described19. Utilizing this
assay, we had excellent reproducibility on duplicate testing (coefficient of variation = .044)
and spike/recovery of rhTGF-β1 (assay standard) into the plasma sample yielded acceptable
results (94.8% of predicted values). In dilutional series, TGF-β1 levels decreased
predictably. The standard curve ranges from 31.2 pg/ml to 2000 pg/ml and the assay has a
lower level of detection of approximately 5 pg/ml.. Serum specimens were diluted 40:1 and
plasma specimens diluted 2:1 to fall within the range of the standard curve. This assay
includes an acidification step per manufacturer’s recommendations which allows for the
measurement of total TGF-β1 protein within the biospecimen.
Microbiology
Respiratory cultures were processed by University of North Carolina McLendon Clinical
Laboratories as previously described20 for the presence of respiratory pathogens. The results
of the admission respiratory culture defined the microbiologic classification (i.e. PsA
positive or negative) of each study subject.
Lung function
Pulmonary function was performed per American Thoracic Society and European
Respiratory Society criteria21 and defined by the percent-predicted FEV1 measured before
the initiation and at the conclusion of antibiotic treatment for the pulmonary exacerbation
during which the blood for TGF-β1 was obtained. FEV1 comparison to a healthy non-CF
reference population utilized NHANES III reference equations22 for children 8–18 years old
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and Eigen’s pre-school specific equations23 for children less than 8 years old. For
comparison of FEV1 within the CF population, Kulich’s CF-specific reference equations
were utilized24.
Statistical Analysis
Descriptive statistics, such as means and standard errors (SEMs) for continuous variables
and frequencies and proportions for categorical variables, were computed for all study
variables of interest. Continuous data were analyzed for normality using stem-and-leaf plots,
normal probability plots, and the Kolmogorov-Smirnov test. All such variables were
determined to follow an approximate normal distribution except for admission TGF-β1,
post-antibiotic plasma TGF-β1, and admission BALF. A further look at the distributions of
these variables indicated that one value for each of these three variables was an outlier. We
confirmed that these values were outliers using the extreme studentized deviate single-
outlier procedure25 (which is the mathematical equivalent to the Grubbs test) and removed
them from further analysis. After outlier removal, continuous data were determined to
follow an approximate normal distribution. Relationships between continuous variables
were examined using the Pearson correlation analysis, and comparisons were performed
using the usual two-group t test, or the two-group t test assuming unequal variances
(Satterthwaite’s method) where needed. The paired t test was used to perform comparisons
between pre-and post-antibiotic therapy plasma, serum, and FEV1 values, and between pre-
and post-Kulich FEV1 values. The exact version of the McNemar test was used to examine
the association between change in lung function and change in plasma TGF-β1 (as illustrated
in Figure 4b). All statistical tests were two-sided and were performed using a significance
level of 0.05. Graphical analyses were performed using GraphPad Prism (version 5.0;
GraphPad Software, Inc., San Diego, CA) and statistical analyses were performed using
SAS (version 9.2; SAS Institute, Inc., Cary, NC).
Results
Clinical characteristics of research participants
Table 1 summarizes the demographics of the study participants. Blood from 40 subjects
hospitalized from January 2007 to March 2008 was analyzed. The mean age of study
subjects (±SEM) was 12.2 ± 0.70 years with an admission FEV1 of 71.8 ± 3.6% predicted
that improved to 84.2 ± 3.3% predicted at the conclusion of treatment. Plasma samples were
available in all 40 subjects and serum samples were available in 39 subjects on admission.
BALF TGF-β1 was available in 15 subjects on admission. Post-antibiotic blood samples
were available in 24 patients, with plasma available in all 24 subjects and serum available in
23 subjects.
Comparisons among plasma, serum and BALF TGF-β1
TGF-β1 was measureable in all plasma, serum and BALF specimens. Utilizing the definition
of an outlier as defined in the methods section, three outlier values were observed: One
admission plasma TGF-β1 value (21, 900 pg/ml), one post-antibiotic plasma value (11,750
pg/ml) and one admission BAL fluid value (844 pg/ml). Excluding these values from further
analysis, plasma TGF-β1 on admission averaged 2450 ± 228 pg/ml. As expected, serum
TGF-β1 levels were more than an order of magnitude higher (72, 800 ± 5390 pg/ml) than
plasma TGF-β1 on admission. BALF TGF-β1 averaged 116.4 ± 23.7 pg/ml. Age was not
associated with admission plasma, serum, or BALF TGF-β1 (p > .20 for all comparisons).
Both admission plasma (r = .33, p = .043) and serum TGF-β1 (r = .47, p = .003) were
associated with admission platelet count, while admission BALF TGF-β1 was not
significantly associated with admission platelet count (r = .43, p = .12).
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Plasma TGF-β1 was positively correlated with BALF TGF-β1 (r = .59, p = .035) as shown in
Figure 1. Serum and plasma TGF-β1 lacked correlation (r = .06, p = .72). Serum TGF-β1
similarly lacked correlation with BALF TGF-β1 (r = −0.001, p = .99 ).
Association between plasma TGF-β1 and clinical parameters of disease
a) Microbiology—The relationship between airway microbiology (PsA culture result) and
plasma TGF-β1 is shown in Figure 2. Twenty-four of 40 (60%) children had a positive
culture for PsA either in BALF or sputum on admission. On admission, plasma TGF-β1 was
significantly increased in patients with an admission respiratory culture positive for PsA
(PsA+: 2880 ± 327 pg/ml; PsA−: 1840 ± 229 pg/ml, p = .014). In contrast, PsA status was
not related to serum TGF-β1 (PsA+: 74, 700 ± 8360 pg/ml; PsA-: 70,100 ± 5590 pg/ml, p = .
65). In addition, neither the presence of Staphylococcus aureus nor Methicillin-resistant
Staphylococcus aureus (MRSA) was associated with elevated plasma or serum protein
levels.
b) Lung function—The relationship between lung function and plasma TGF-β1 is shown
in figure 3. To determine if TGF-β1 was increased in subjects with more advanced lung
disease, subjects were dichotomized to those who maintained an FEV1 above or equal to
80% predicted values on admission for a pulmonary exacerbation (“mild impairment”) and
those whose lung function was below 80% on admission (“moderate to severe impairment”).
Mean FEV1 in the “mild impairment” group was 93.2 ± 2.5% (n=16) compared to 55.4 ±
2.7% (n=21) in the “moderate to severe impairment” group, p < .001. Plasma TGF-β1 was
significantly increased in the “moderate to severe impairment” as compared to the “mild
impairment” group (2940 ± 373 pg/ml vs. 1920 ± 201 pg/ml, p = .023). In contrast, serum
TGF-β1 was actually increased in the “mild impairment” group [91,000 ± 8000 pg/ml vs.
63,500 ± 6800 pg/ml, p = .013); the subject with the highest serum TGF-β1 (164,000 pg/ml)
had an FEV1 of exactly 80% predicted].
In an attempt to categorize subjects based upon the relative status of CF lung disease,
subjects were also stratified utilizing the Kulich CF-specific reference equations23 for age,
height and FEV1 (L) developed for subjects with CF between 6–40 years of age. In contrast
to non-CF, non-diseased reference equations in which 100% is considered “normal”, Kulich
values >50% are considered above normative values and Kuhlich values <50% are
considered below normative values. Kulich FEV1% was 41.8 ± 4.9 % on admission that
improved to 59.9 ± 4.8 % after completion of therapy (p < 0.001).
Research subjects were subsequently dichotomized according to whether their lung function
returned to above or below the CF-specific normative value (50th percentile) after the
completion of therapy. Admission plasma TGF-β1 was significantly higher (3580 ± 597 pg/
ml vs. 2085 ± 215 pg/ml, p = .038) in subjects whose lung function remained below
normative values after the completion of antibiotic therapy compared to those whose lung
function returned to above normative values. Utilizing this same lung function stratification,
serum TGF-β1 did not differ between subject groups (p = .48).
c) Recurrent hospitalization—Slightly more than half (20/39, with information missing
on one individual) of research participants were hospitalized in the 12 months prior to the
current exacerbation. Neither plasma nor serum TGF-β1 was significantly increased in those
recently hospitalized compared to those who had not been hospitalized in the last year (p =
0.10 and 0.38, respectively).
d) Response to antibiotic therapy—Post-antibiotic blood specimens were available for
analysis in 24/40 subjects. Reasons for missed samples at the conclusion of antibiotic
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therapy included completion of antibiotics at home, extension of antibiotics beyond the
follow-up clinic visit and inability to obtain an adequate sample from the central PICC line.
In the subset of subjects with follow-up specimens available, mean age was 13.0 ± 0.8 years
with 16/24 subjects positive for PsA on admission. Correlation between pre-therapy and
post-therapy TGF-β1 was strong for plasma (r = .90, p < .001) and weak for serum (r = .21,
p = .33). In the subset of subjects with both pre-therapy and post-therapy samples, FEV1
improved from 64.3 ± 3.7 % predicted to 81.2 ± 3.8% predicted (p < .001) after treatment of
their pulmonary exacerbation. In association with this improvement in pulmonary function,
plasma TGF-β1 decreased from 2600 ± 360 pg/ml to 1770 ± 227 pg/ml (p < .001). Plasma
TGF-β1 was reduced in 83% of subjects after antibiotic therapy (p < .001). In contrast,
serum TGF-β1 was unchanged before and after therapy (Pre: 59,570 ± 7060 pg/ml, Post:
56,160 ± 5390 pg/ml, p = .67). Similar to admission plasma TGF-β1, post-therapy plasma
TGF-β1 tended to be increased in subjects whose lung function remained below normative
CF-specific values after the completion of therapy. In these patients with persistently
depressed lung function, post-therapy plasma TGF-β1 was 2660 ± 525 pg/ml compared to
1430 ± 167 pg/ml in subjects with above normative values (p = .059). Serum TGF-β1 was
not significantly different between groups. The relationships between improved lung
function and diminished plasma TGF-β1 are shown in Figure 4.
e) Genotype—Although this study was not designed nor sufficiently powered to evaluate
for significant associations between TGF-β1 genotype and plasma TGF-β1 protein
concentrations, all subjects were genotyped for TGF-β1 codon 10 polymorphisms.
Consequently, we report the data to help with future sample size calculations.
On admission, no significant difference was detected in plasma TGF-β1 by genotype (TT:
2300 ± 395, n=17; CT: 2580 ± 358, n=16; CC: 2565 ± 315, n=6; p = .84 by ANOVA).
Combining the subjects with one C polymorphism, we similarly did not see a significant
difference by genotype (TT: 2300 ± 395, n=17; CT/CC: 2580 ± 270, n=22; p = .55 by t-test
analysis). These analyses do not include the one outlier in admission plasma TGF-β1
measurement (21,900, CT genotype).
At follow-up, no significant difference was detected by ANOVA across the three genotypes
although the sample size was even more limited (TT: 1520 ± 333, n=13; CT: 1930 ± 311,
n=8; CC: 2740 ± 450, n=2; p = .31 by ANOVA). Comparing subjects with one C
polymorphism, we similarly did not find significance (TT: 1520 ± 333, n=13; CT/CC: 2090
± 276, n=11; p=.22). These analyses do not include the one outlier in follow-up plasma
TGF-β1 measurement (11,750, CT genotype). Of note, we performed these analyses
utilizing parametric techniques as described in the methods section.
Discussion
We have found that in pediatric CF, plasma TGF-β1 is increased in association with PsA
infection and diminished lung function, and is reduced in association with clinically-
effective treatment for a pulmonary exacerbation. Furthermore, our data underscore that
TGF-β1 protein measurements are not interchangeable between platelet-free plasma and
serum. Specifically, serum TGF-β1 levels were >20-fold higher than plasma levels with no
correlation between serum TGF-β1 and either plasma or BALF TGF-β1. In contrast, plasma
TGF-β1 was significantly correlated with BALF TGF-β1 with a consistent decrease in
plasma TGF-β1 associated with a clinically-meaningful response to therapy. Our data thus
support exploration of platelet-free plasma TGF-β1 as a peripheral biomarker of CF lung
disease in childhood, and suggest a negative relationship between elevated TGF-β1 protein
levels and lung function in pediatric CF lung disease.
Harris et al. Page 6













When plasma is utilized for studies of TGF-β1, careful attention must be placed on the
method of plasma processing to limit the contribution of activated platelet degranulation ex
vivo. In our experience, important technical steps include prevention of coagulation
(immediate processing), collection through a central venous catheter if available, selection
of the appropriate specimen tube (citrate preferred as both heparin and EDTA can activate
TGF-β1), adequate centrifugation (to segregate a platelet-free fraction) and use of a sensitive
and specific TGF-β1 detection assay. Utilizing these techniques, the plasma levels of TGF-
β1 in this study of CF patients were consistent with those reported in the literature from
optimally collected plasma specimens10,11,13,26. Our results prompt critical review of
previous literature linking TGF-β1 genotype with TGF-β1 protein measurements in blood.
Our data suggest that serum TGF-β1 is of limited relevance to CF lung disease phenotype
compared to plasma. Moreover, for studies that evaluate the association of TGF-β1 genotype
and plasma TGF-β1 protein, the methods of plasma acquisition and processing should be
carefully considered.
While aberrant inflammatory cytokine profiles are well-documented in CF BALF
specimens17,27,28,29, parallel findings of altered cytokine protein levels in the peripheral
circulation have been limited. To our knowledge, this is the first study which has
demonstrated a significant correlation between plasma and BALF TGF-β1 in the pediatric
CF population. Additionally, the correlation between plasma and BALF TGF-β1 in the
context of TGF-β1 as disease modifier of CF lung disease severity1,2,4,30 suggest that plasma
TGF-β1 may hold promise as a relatively noninvasive biomarker to assess CF lung disease.
While this study indicates that plasma TGF-β1 meets the classic definition of a biomarker as
an objectively-measureable biologically-relevant characteristic31, future studies as
delineated by Mayer-Hamblett et al32 will be necessary to evaluate its full utility as a CF
biomarker. These include assessment of its clinical and therapeutic relevance, sensitivity and
specificity across a variety of clinical scenarios, reproducibility within the same patient and
across CF centers, and feasibility for wide-spread collection.
The potential utility of plasma TGF-β1 to track CF lung disease is further underscored by the
association of increased plasma TGF-β1 with PsA infection and diminished lung function
(Figs 2 and 3). While the mechanisms of these associations are beyond the scope of this
study, our data point towards relationships between increased TGF-β1 levels and disease
severity. It is not clear whether elevated TGF-β1 levels represent a cause or consequence of
CF lung disease, but the reduction of TGF-β1 plasma levels in response to treatment may
identify a useful biomarker for CF therapeutic interventions, and possibly a target for
disease modification.
One important finding of this study was the significant association between an elevated
admission plasma TGF-β1 and lung function that remains below normative values despite
antibiotic therapy. Increased cytokine measurement during the time of exacerbation has been
felt to reflect airway inflammation, and we have previously shown an association between
neutrophilic inflammation and BALF TGF-β119. However, the link between elevated TGF-
β1 (a potent pro-fibrotic mediator) at the time of admission and lung function at the
conclusion of conventional therapy suggests that TGF-β1 may play a role in pathogenic
airway remodeling that is refractory to traditional therapy. Supportive of this hypothesis is
data from Hilliard et al29 that reveals a significant association between BALF TGF-β1 and
reticular basement membrane thickness demonstrated by endobronchial biopsy. Thus, we
speculate that TGF-β1 may bridge the inflammatory and remodeling pathways in CF,
serving as one potential mechanism through which TGF-β1 may modify CF lung disease
progression.
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An important caveat of this study is that we measured and correlated total TGF-β1 protein
levels rather than the transient, biologically active form in tissue compartments. Total and
active TGF-β1 are not always highly correlated and local activation is a tightly regulated
process that independently influences biologic effect33.
We additionally recognize the limitation that this study was not designed to identify the
sources of plasma TGF-β1. The positive correlation between both BALF TGF-β1 and
platelet count suggests both a pulmonary and platelet contribution to plasma TGF-β1. While
an association is to be expected as platelets are reported to be a major source of circulating
TGF-β110, future studies could consider the use of a specific marker of ex vivo degranulation
such as Platelet Factor 4 (PF4) to insure that measured protein levels represent circulating
levels rather than an artifact of specimen processing.
Finally, the relatively small sample size limited our ability to perform multivariable
analyses, such as multiple regression analyses with inflammatory cytokines, as well as
limiting our ability to form conclusions about TGF-β1 genotype-phenotype relationships.
Using an odds ratio for disease of 2.2 and a predicted prevalence of the codon 10 CC
genotype of 13–17%2,3, a study population of several hundred subjects would be necessary
to detect significant associations between TGF-β1 genotype, protein concentration and
disease severity. Instead, we chose to focus this single-center study on emphasizing the
importance of TGF-β1 biospecimen selection and processing by emphasizing relationships
with key clinical parameters. Our results help lay the foundation for larger multi-center
studies to examine TGF-β1 genotypes, their relationship with TGF-β1 protein levels and
clinical outcome measures.
Despite these considerations, our findings suggest that plasma TGF-β1 should be included in
future CF biospecimen profiles with further investigation of the mechanisms through which
TGF-β1 may modulate CF lung disease progression. The results of this study provide
evidence that plasma is the preferred blood biospecimen for measuring TGF-β1 protein
levels in CF, as plasma TGF-β1 correlates with BALF levels and fluctuates in association
with several important parameters of CF lung disease severity. Whether plasma TGF-β1 is a
potentially useful biomarker of disease progression or response to therapy merits further
investigation.
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Correlation between plasma and BALF TGF-β1 at admission (r = .59, p = .035) by Pearson
coefficient analysis.
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Association between plasma TGF-β1 levels and Pseudomonas aeruginosa positive (PsA+)
respiratory culture at admission. TGF-β1 is significantly increased in PsA+ subjects (2880 ±
327 pg/ml vs. 1840 ± 229 pg/ml, p = .014) admission.
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A) Association between plasma TGF-β1 and lung function on hospital admission. Plasma
TGF-β1 is significantly increased in CF subjects with forced expiratory volume in 1 second
(FEV1) of less than or equal to 80% predicted values (Low FEV1: 2940 ± 373 pg/ml; High
FEV1: 1920 ± 201 pg/ml, p = .023)
B) Association between plasma TGF-β1 and lung function after the completion of therapy.
Plasma TGF-β1 on admission is significantly increased in CF subjects whose FEV1 remains
below CF-specific normative values at the conclusion of antibiotic therapy (Low post-
therapy FEV1: 3580 ± 597 pg/ml; High post-therapy FEV1: 2085 ± 215 pg/ml, p = .038)
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A) Response of plasma TGF-β1 to treatment of a pulmonary exacerbation. After the
conclusion of clinically-directed treatment, plasma TGF-β1 decreases from 2600 ± 360 pg/
ml to 1770 ± 227 pg/ml (p < .001).
B) Association between improved lung function (FEV1) and reduced plasma TGF-β1 during
treatment of a pulmonary exacerbation. After standard clinically-directed therapy, plasma
TGF-β1 is reduced in 83% of subjects (p < .001).
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Table 1
Demographics and clinical characteristics of study subjects. Data are presented as mean ± SEM or as fraction
of subset (%).
Age (Range) 12.2 ± 0.7 years (1–19 years)
Gender, (female/total)% (19/40) 47.5%
BMI percentile 35.6 ± 4.7%
Genotype
 CFTR
  %ΔF508/ΔF508 (16/39) 41.0%
  %ΔF508/other (20/39) 51.3%
  %other/other (3/39) 7.7%
 TGFB1 codon 10 genotype
  %TT (17/40) 42.5%
  %CT (17/40) 42.5%
  %CC (6/40) 15.0%
Lung function: FEV1 (% predicted)
 Pre-antibiotics 71.8 ± 3.6 %
 Post-antibiotics 84.2 ± 3.3%
Microbiology,
% positive bacterial respiratory culture 36/40 (90%)
 % polymicrobial   28/36 (78%)
 % Pseudomonas aeruginosa   23/36 (64%)
   % mucoid phenotype    14/23 (61%)
 % Staphylococcus aureus   23/36 (64%)
  % methicillin-resistant    16/23 (70%)
Hospitalizations
Frequency 0.87 ± .17 hospitalizations/year
% hospitalized in last 12 months (20/39) 51.3%
Abbreviations: FEV1% (Forced expiratory volume in 1 second as a percentage of predicted values in healthy non-CF subjects, BMI (Body Mass
Index)
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